ocrelizumab
E518760
disease-modifying therapy
humanized monoclonal antibody
monoclonal antibody
multiple sclerosis medication
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
disease-modifying therapy
ⓘ
humanized monoclonal antibody ⓘ monoclonal antibody ⓘ multiple sclerosis medication ⓘ |
| approvedFor | adults ⓘ |
| ATCCode | L04AA36 ⓘ |
| belongsToClass | IgG1 monoclonal antibodies ⓘ |
| bindingTargetLocation | B lymphocytes NERFINISHED ⓘ |
| CASNumber | 679818-59-8 ⓘ |
| commonAdverseEffect |
headache
ⓘ
herpes virus infections ⓘ infusion-related reactions ⓘ upper respiratory tract infections ⓘ |
| contraindication | active hepatitis B infection ⓘ |
| developer |
Genentech
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| dosingInterval | every 6 months ⓘ |
| effectOnImmuneSystem | selective depletion of CD20-expressing B cells ⓘ |
| FDAApprovalYear | 2017 ⓘ |
| halfLife | approximately 26 days ⓘ |
| hasBrandName | Ocrevus NERFINISHED ⓘ |
| indication |
active secondary progressive multiple sclerosis
ⓘ
primary progressive multiple sclerosis ⓘ relapsing forms of multiple sclerosis ⓘ relapsing-remitting multiple sclerosis NERFINISHED ⓘ |
| initialDoseRegimen | two 300 mg intravenous infusions 2 weeks apart ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| maintenanceDose | 600 mg intravenous infusion every 6 months ⓘ |
| mechanismOfAction |
B cell depletion
ⓘ
antibody-dependent cell-mediated cytotoxicity ⓘ complement-dependent cytotoxicity ⓘ |
| pharmacologicClass |
immunomodulator
ⓘ
selective immunosuppressant ⓘ |
| reduces |
MRI lesion activity in multiple sclerosis
ⓘ
multiple sclerosis relapse rate ⓘ |
| regulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| requires |
premedication with corticosteroids and antihistamines before infusion
ⓘ
screening for hepatitis B virus before initiation ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| slows | disability progression in multiple sclerosis ⓘ |
| targets |
CD20 antigen
NERFINISHED
ⓘ
CD20-positive B cells ⓘ |
| UNII | D2RT4KQ1E4 ⓘ |
| warning |
increased risk of infections
ⓘ
possible increased risk of malignancy ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.